Seeking Alpha News (Tue, 11-Aug 7:11 AM ET)
Globe Newswire (Tue, 11-Aug 7:05 AM ET)
NeurAxis Expands Medical Policy Coverage for IB-Stim, Reaching Over 500,000 New Lives
Market Chameleon (Tue, 4-Aug 4:05 AM ET)
NeurAxis Expands Payer Coverage with New Policies
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
Globe Newswire (Tue, 28-Jul 7:00 AM ET)
NeurAxis Achieves 33% Revenue Growth in 2025 Driven by Expanded Insurance Coverage and FDA Approvals
Market Chameleon (Thu, 19-Mar 3:55 AM ET)
Market Chameleon (Fri, 19-Dec 5:33 AM ET)
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Neuraxis trades on the AMEX stock market under the symbol NRXS.
As of August 13, 2026, NRXS stock price climbed to $6.45 with 62,660 million shares trading.
NRXS has a beta of 0.54, meaning it tends to be less sensitive to market movements. NRXS has a correlation of 0.01 to the broad based SPY ETF.
NRXS has a market cap of $81.00 million. This is considered a Micro Cap stock.
Last quarter Neuraxis reported $2 million in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-71,305 and exceeded earnings estimates by $.13.
In the last 3 years, NRXS traded as high as $9.33 and as low as $1.33.
The top ETF exchange traded funds that NRXS belongs to (by Net Assets): VTI, VXF, IWC, BUSM.
NRXS has outperformed the market in the last year with a price return of +159.0% while the SPY ETF gained +22.1%. However, in the short term, NRXS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -22.0% vs +5.5% return in SPY. But in the last 2 weeks, NRXS shares have fared better than the market returning +6.8% compared to SPY +6.5%.
NRXS support price is $6.02 and resistance is $6.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRXS shares will trade within this expected range on the day.